Payment overview · 2025
General Payments
$1,051.09
27 reported records · 12 companies
Healthcare provider profile · identity verified
Emmanuel Valery, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1750334157
Verified facts
What the public records show
CMS Open Payments records show Emmanuel Valery, MD received $1,051.09 in general payments during 2025 across 27 reported records.
ABIOMED accounted for 26.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Airsupra, Farxiga, Kerendia, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 516 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 462 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABIOMED | Unresolved — no canonical attribution shown | $274.96 | 26.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $263.46 | 25.1% | 7 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $152.62 | 14.5% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $87.27 | 8.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $59.30 | 5.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.32 | 4.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.24 | 4.1% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $34.99 | 3.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $28.43 | 2.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $25.70 | 2.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.42 | 1.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.38 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,051.09 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $180.12 | 3 | 2025 |
Source payment records
|
|||||
| Livdelzi Normalized: livdelzi |
Drug | Gilead Sciences, Inc. | $118.71 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $87.27 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $59.97 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $59.30 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $59.30 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $46.32 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $43.24 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $34.99 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $28.43 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $25.70 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $23.37 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.42 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.42 | 1 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 21 | exact normalized | Medicare Part D |
| AIRSUPRA airsupra |
2025 | Airsupra | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 516 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 159 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 171 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 129 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
516 | 132 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
40 | 22 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
159 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
462 | 119 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
171 | 46 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
129 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
173 | 37 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1214 | 394 |
| Diclofenac Sodium | Diclofenac Sodium | 645 | 190 |
| Metformin Hcl | Metformin Hcl | 598 | 183 |
| Amlodipine Besylate | Amlodipine Besylate | 588 | 193 |
| Losartan Potassium | Losartan Potassium | 545 | 162 |
| Farxiga | Dapagliflozin Propanediol | 516 | 132 |
| Jardiance | Empagliflozin | 462 | 119 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 461 | 161 |
| Carvedilol | Carvedilol | 398 | 106 |
| Pantoprazole Sodium | Pantoprazole Sodium | 391 | 102 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 365 | 116 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 277 | 81 |
| Famotidine | Famotidine | 271 | 68 |
| Gabapentin | Gabapentin | 271 | 75 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 264 | 86 |
| Tamsulosin Hcl | Tamsulosin Hcl | 227 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 204 | 60 |
| Omeprazole | Omeprazole | 204 | 52 |
| Hydralazine Hcl | Hydralazine Hcl | 202 | 52 |
| Zolpidem Tartrate | Zolpidem Tartrate | 192 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 177 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 177 | 48 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 177 | 40 |
| Meloxicam | Meloxicam | 175 | 61 |
| Eliquis | Apixaban | 173 | 37 |
| Mounjaro | Tirzepatide | 171 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 163 | 53 |
| Kerendia | Finerenone | 159 | 38 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 159 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 158 | 56 |
| Nifedipine Er | Nifedipine | 153 | 35 |
| Ammonium Lactate | Ammonium Lactate | 151 | 44 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 145 | 63 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 142 | 29 |
| Latanoprost | Latanoprost | 139 | 38 |
| Enalapril Maleate | Enalapril Maleate | 133 | 35 |
| Furosemide | Furosemide | 133 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 132 | 45 |
| Ketoconazole | Ketoconazole | 130 | 50 |
| Ozempic | Semaglutide | 129 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 123 | 38 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 121 | 41 |
| Novolog Flexpen | Insulin Aspart | 114 | 26 |
| Levothyroxine Sodium | Levothyroxine Sodium | 112 | 28 |
| Donepezil Hcl | Donepezil Hcl | 105 | 20 |
| Single Use Swab | Alcohol Antiseptic Pads | 103 | 33 |
| Lisinopril | Lisinopril | 98 | 33 |
| Montelukast Sodium | Montelukast Sodium | 98 | 28 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 93 | 30 |
| Finasteride | Finasteride | 90 | 22 |
| Alendronate Sodium | Alendronate Sodium | 88 | 20 |
| Repaglinide | Repaglinide | 84 | 24 |
| Levetiracetam | Levetiracetam | 83 | 16 |
| Spironolactone | Spironolactone | 83 | 28 |
| Meclizine Hcl | Meclizine Hcl | 82 | 29 |
| Levemir Flexpen | Insulin Detemir | 78 | 18 |
| Hydrocortisone | Hydrocortisone | 74 | 21 |
| Simvastatin | Simvastatin | 74 | 21 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 73 | 22 |
| Tramadol Hcl | Tramadol Hcl | 73 | 22 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 72 | 23 |
| Prednisone | Prednisone | 70 | 31 |
| Glipizide | Glipizide | 69 | 24 |
| Lidocaine | Lidocaine | 69 | 18 |
| Ibuprofen | Ibuprofen | 67 | 25 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 67 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 23 |
| Pregabalin | Pregabalin | 63 | 14 |
| Ezetimibe | Ezetimibe | 61 | 21 |
| Lactulose | Lactulose | 59 | 12 |
| Labetalol Hcl | Labetalol Hcl | 56 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 13 |
| Xarelto | Rivaroxaban | 55 | 15 |
| Naproxen | Naproxen | 53 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 51 | 16 |
| Januvia | Sitagliptin Phosphate | 49 | 13 |
| Atenolol | Atenolol | 48 | 16 |
| Chlorthalidone | Chlorthalidone | 47 | 14 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 45 | 38 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 44 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | suppressed |
| Tradjenta | Linagliptin | 43 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 43 | 13 |
| Alcohol Pads | Alcohol Antiseptic Pads | 42 | 12 |
| Trulicity | Dulaglutide | 42 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 41 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 41 | 20 |
| Sertraline Hcl | Sertraline Hcl | 41 | 12 |
| Memantine Hcl | Memantine Hcl | 40 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 40 | 22 |
| Azithromycin | Azithromycin | 39 | 35 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Glipizide Er | Glipizide | 38 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 38 | suppressed |
| Sucralfate | Sucralfate | 37 | suppressed |
| Comfort Ez Pro Safety Pen Ndl | Pen Needle, Diabetic, Safety | 36 | 12 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 36 | 12 |
| Timolol Maleate | Timolol Maleate | 34 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | 12 |
| Celecoxib | Celecoxib | 33 | 11 |
| Dapagliflozin | Dapagliflozin Propanediol | 33 | 21 |
| Pure Comfort Alcohol Pad | Alcohol Antiseptic Pads | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 31 | 12 |
| Entresto | Sacubitril/Valsartan | 30 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 29 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 28 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 27 | 13 |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| True Comfort Safety Pen Needle | Pen Needle, Diabetic, Safety | 23 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 15 |
| Risperidone | Risperidone | 22 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 21 | 21 |
| Cilostazol | Cilostazol | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Meloxicam | Meloxicam, Submicronized | 19 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 18 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 17 | suppressed |
| Minoxidil | Minoxidil | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 16 |
| Trazodone Hcl | Trazodone Hcl | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Allopurinol | Allopurinol | 12 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Calcium Acetate | Calcium Acetate | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,051.09 · 27 records | ABIOMED | ABRYSVO, AIRSUPRA, BREZTRI, Biktarvy, COMIRNATY, FARXIGA, FREESTYLE LIBRE 3, IBSRELA, Kerendia, Livdelzi, MOUNJARO, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, The Cologuard Plus Collection Kit, VOQUEZNA, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error